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[WeP1081 Resistance to macrolides in a group A Streptococci
in pharyingeous samples
The phenotype pattern resistance ofthe 55 strains studied was: constitutive
resistance 5.45%, inducible resistance 27.27% and M phenotype 67.27%. In
M phenotype (38 strains) we tested CMI to erythromycin (> 4). clinda-
mycin ( < = 0.5) and josamycin ( < 0.03-0.06, 91.89% and < 0.125-0.25,
8.10%). A sensibility correlation between clindamycin and josamycin was
observed.
COndusions: Due to the high percentage of resistance in our area, it is
necessary to test erythromycin resistance in group A Streptococci and to
know the prevalence ofM phenotype because ofits importance in the choice
of an appropriate antibiotic therapy in the clinical practice.
P. Liendo, M.J. Unzaga, P. Velasco, M. B. Amezua. R. Cisterna
CIi,lical Microbiology and Infection Control Department, Hospital de BaSlIrlO,
Osakidetza, Bilbao, Spain
Objectives: Knowledge of the incidence oferythromycin resistant in group
A Streptococci in pharyingeous sampl~ from t995 to t999. We also studied
the models of macrolides resistance in the strains resistant to erythromycin
fTOm October of t998 to December of 1999.
Methods: We carried out a retrospective study of group A Streptococci
isolated in the Hospital of Basurto between 1995 and 1999. The Hospital of
Basurto is a 800 bed primary and tertiary care, teaching hospital that
provides care in the urban area of Bilbao (Spain). In our study of the
phenotype pattern of erythromycin-clindamycin resistance a double-disk
test was used.
Results: Erythromycin resistance in the different years:
IWeP110IPrevalence. phenotypes and genetics of macrolide-
resistant S. pyogenes in Austria
C. Jebelean!, I. Krieberneg~2, G. Feierl2, A. Bocksrucker·, R.
Watschingerl , M. Haditsch , L. Binder·, H. Mittermayer1
IElisabethinerr Hospital Linz; 2Karl Franzerrs Univ. Graz, Austria
Objectives: to investigate the prevalence, phenotypes and genetics of
macrolide-resistant S. pyogenes in Austria.
Materials and Methods: We began to monitor thc susceptibility of S.
pyogene5 strains in our institution in 1994. During 1999 we also collected
strains from other regions in Au.~tria. 323 strains were examined using the
agar dilution method on Mueller-Hinton agar supplemented with 5% sheep
blood for susceptibility to erythromycin (E), tetracycline (T) and clinda-
mycin (CI). 145 strains were also examined for azithromycin (An), clari-
thromycin (Cia), roxithromycin (Ro) and josamycin susccptibility. We
determined the macrolide resistance phenotype using a double-disk test with
E and CI. We used a PCR method to detect we the presence of mefA,
ermAM and ermTR genes.
Results: The prevalence ofantibiotic resistance varied from 1994 to 1999: E-
resistance decreased from 18% to II % and T-resistance increased from 5%
to 17%. Out of61 E-rcsistant strains we found the following phenotypesf
genes: 43 with MfmefA; 8 with MLSBfermAM; 7 with inducible MLSBf
ermTR and 3 with erm + mef. E-resistant strains were also resistant to Azi,
CIa and Ro. Josamycin MIC were all S; 0.25 Ilgfml with the exception of
constitutive MLSB strains which had an MIC of ~8 ~ml.
Conduslons: We conclude that erythromycin resistance of S. pyogenes in
Austria has become infrequently and varies regionally; the M-resistant
phenotype is the most predominant;josamycin may constitute an alternative
for E-resistant strains with M-type; susceptibility testing is recommended for
situations in which macrolides are chosen.
P:5/9 - Quinolones
IWeP112! Bactericidal activity of ciprofloxacin and
levofJoxadn on 5. Pneumoniae at various phases of growth
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IWeP1 091 Susceptibility of Portuguese Haemophi/us
influenzae isolates to azythromydn. c1arithromycin and
erythromycin
M. P. Lavado. D. Louro, M. M. Cani~a
NIH Dr. Ricardojorge, Lisbon, Portugal
Objectives: To evaluate the comparative in vitro antibacterial activity of
three macrolides against portuguese clinical isolates of Haemophilus injluen-
zae (Hi).
Methods: MICs (agar dilution method, NCCLS, 1999) of azythromycin.
clarithromycin and erythromycin were determined against 150 isolates ofHi
(50 ,a-Iactamase producers, bl + 100 non ,a-Iaetamase producers. bl-). {3-
lactamase production was detected with nitrocefin. Strains. collected from
10 clinical laboratories. had the following characteristics: 97% - respiratory
tract, 79% - children; 92% - outpatients.
Results: MIC50 and MIC90 were as follow (mgfL):
100 Hi bl- 50 Hi b1+
MIC MIC
Antibiotic MIC50 MIC90 range MIC50 MIC90 range
Erythromycin 2 2 <0.06-8 2 4 1-4
Clarithromycin 2 4 :0;0.06-164 8 1-8
Azythromycin 0.25 0.5 :0;0.06-2 0.5 I 0.25-2
The rank order of activity on a weight basis was: azithromycin >
erythromycin ~ clarithromycin. For erythromycin 92% of strains were
classified as intermediate; 2 (I %) strains were resistant to this antibiotic. All
strains were susceptible to the other macrolides.{3-laetamase production did
not significantly influence the antimicrobial activity ofthe macrolides tested.
COnclusions: These results arc similar to the ones observed in other coun-
tries: azithromycin was fourfold more active than erythromycin, which was
slightly more active than clarithromycin. Erythromycin had poor activity
with a susceptibility rate of 7%. The newer macrolides are an interesting
alternative for therapy of Hi infections, since they showed to bc potent
agents against ampicillin resistant as well as ampicillin susceptible strains.
F. Scaglione. G. Demartini, S. Dugnani, F. Fraschini
Dept. ofPharmacology, University ofMilano, Italy
Streptococcus pneumoniae is a microorganism, which frequently colonizes the
upper respiratory tract. and represent an important cause of bacterial
pneumonia and meningitis. In the past pneumococci were found to be
extremely susceptible to both beta-Iaetam and macrolide antibiotics. How-
ever in the last decade there have been several reports of increased penicillin
resistance among pneumococcal strains isolated in several different countries.
New quinolones could represent a valid alternative in the therapy of
pneumococcal diseases. Previous study showed that old quinolones posses
different bactericidal effect at various phases of bacterial growth.
The aim of the study was to determine the bactericidal activity of
ciprofloxacin and levofloxacin against one recent clinical isolate ofpenicillin
resistant Streptococcus pneumoniae (MIC 2 mgfL). Time-kill studies were
performed over a 24 h period with sampling at 0, 4, 8 and 24 h. Isolates were
tested at a concentration oft X MIC.2 x MIC and 4 X MIC against bacteria
in logarithm growth phase and in stationary phase. Levofloxacin was found
to have an antibacterial activity comparable to that of ciprofloxacin against
bacteria in logarithm growth phase. Against bacteria in stationary phase.
levofloxacin showed a bactericidal effect (3-log reduction ofbacterial size) at
all concentrations tested, while ciprofloxacin was found bactericidal only at
the higher concentration. This data may support the hypothesis that several
mechanisms are involved in the concentration-dependent activity ofquino-
lones. Particularly the nucleic acid synthesis may play an important role.
IWeP1131 Susceptibility to moxifloxadn and other
antimicrobial agents of major pathogens responsible for
community acquired infections of respiratory tract
K. Betlejewska, M. Turzynska. W. Hryniewicz
Sera & Vaccines Central Research Laboratory, Warsaw, Poland
Objectives: To determine susceptibility to moxifloxacin and other anti-
microbial agents of major pathogens responsible for community acquired
respiratory tract infections.
Methods: Altogether 500 bacterial strains isolated in 1999 in different
regions of Poland from patients with upper (n 0; 223) and lowcr (n =
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277) respiratory tract infections were tested. They were identified to the
species level by standard procedures. Two hundred and fifty S. plleumoniae,
120 H. injluenzae, 80 M. catarrhalis and 50 S. pyogenes strains were arbitrarily
selected and they represented various resistance phenotypes according to the
preliminary data obtained by disc-diffusion method. MICs were determined
either by agar dilution (H. injluenzae, M. catarrhalis) or broth microdilution
(S. pneumoniae, S. pyogenes) method according to the NCCLS guidelines.
Results: All the coIlected strains were susceptible to moxiftoxacin with
MIC90 ofO.l2 /-Ig/ml for penicillin-susceptible and penicillin-intermediate
S. pneumoniae, and H. i'!fluenzae, and ofO.25/-1g/ml for penicillin-resistant S.
plleumoniae, S. pyogenes and M. catarrhalis. The MIC90 ofciproftoxacin was 8
/-Ig/ml for penicillin-susceptible and penicillin-intermediate S. pneumoniae, 1
JLg/ml for H. injluenzae, 16 JLg/ml for penicillin resistant S. pllellmoniae, and
0.06 JLg/ml for M. catarrhalis. Penicillin-intermediate S. pneumoniae strains
were frequently resistant to amoxicillin (11.0%). cefotaxime and ceftriaxonc
(13.9%). erythromycin (44.0%) and trimethoprim/sulfamethoxazole
(41.2%). Penicillin-resistant S. pneumoniae were resistant to amoxicillin
(55.4%). cefotaximc and ccftriaxonc (55.4%). erythromycin (36.5%) and
trimethoprim/sulfamethoxazole (77.0%). Penicillin-susceptible S. p"eumo-
Iliae isolates demonstrated much lower degree of resistance (erythmmycin.
23.6%; trimethoprim/sulfamethoxazole. 26.4%). A significant number ofS.
pyogenes strains was resistant to erythromycin (12.0%).
Conclusions: Moxifloxacin demonstrated a very good in vitro activity
against major pathogens responsible for community acquired respiratory
tract infections.
IWeP1141 Activity of gatifloxadn compared to other
antimicrobial agents against 658 strains isolated from patients
with respiratory tract infections, in three medical centers from
Argentina
J. Smayevsky'. H. LOpeZ2. M. Di Chiara'. S. Scaran02• Alejandra Lanza.
V. Vilches2, D. Stepanik2, C. Bantarl , A. Sucari2.3
'C.E.M.I.C.; 2Centro de Infeetologia; JClinica del Sol, Buetlos Aires,
Argentina
Gatiftoxacin (GAT) is a new fluoroquinolone with enhanced activity against
gram positive bacteria. The aim of this study was to compare the it' vitro
activity of GAT against 658 isolates recovered from adult outpatients (i.e.
173 Streptocoaus pneumoniae {Sp. 128 penicillin-susceptible. 32 penicillin-
intermediate and 13 penicillin-resistant}; 163 Haemophilus injluenzae {Hi.
128 iJ-lactamase non-producers (BL-). Hi. 35 iJ-lactamase-producers
(BL+ )}; 111 Moraxella catarrhalis {Me, 9 BL-. 102 BL+}. 95 Streptocoaus
pyogenes (Spy) and 116 Staphylococcus aureus {Sa. 96 mcthiciJIin-sensible. 20
methicillin-resistant} strains). MICs of GAT. ciproftoxacin (CIP).levoftox-
acin (LEV). cefuroxime. ceffriaxone. clarithromycin (CLA) and ampicillin-
sulbactam were assayed. AIl MICs were determined by the agar dilution
method foIlowing the NCCLS guidelines. Percentage of CLA resistance in
Hi, Sp and Spy was 5.5. 7.5 and 6.3, respectively. M1C90 values (mgfl) for
the quinolones tested are given in the following table.
Results
MIC90 (mg/I)
N° CIP LEV GAT
S. pneumcmiat 173 2 I 0.5
H. inftutnzat' 163 0.06 0.06 0.06
M. cata"halis 111 0.06 0.06 0.06
S.pyogenes 95 1 0.5 0.25
s. aurt'us 116 16 4 2
GAT proved to be active against most ofthe respiratory pathogens tested.
including allthe penicillin-resistant Sp strains. Hi BL + and Me BL +
isolates.
IWeP11Slin vitro activity of moxifloxadn and other oral
agents against antibiotic resistant Streptococws pneumoniae
J. Black, E. SmithMoland, S. Chartrand, K. Thomson
Creighton University, Omaha, Utlited States
Multiple antibiotic resistance in S. pneumoniae is a worldwide problem. New
effective oral agents are needed for therapy of infections caused by resistant
strains.
Objectives: A study was designed to evaluate the activity of moxifloxacin.
levoftoxacin. penicillin. amoxicillin/clavulanate, cefdinir, cefpodoxime.
cefprozil. loracarbef, azithromycin, and clarithromycin against a panel of
153 clinical isolates of S. pneumoniae (38% susceptible to penicillin. 43%
intermediate, and 19% resistant).
Methods: Agar dilution MICs were determined using Mueller-Hinton agar
supplemented with 5% sheep blood.
Results: Moxiftoxacin was the most potent agent with all isolates inhibited
by 0.25 JLg/mI. It was 8- to 16-fold more potent than levofloxacin and was
equally active against penicillin-sensitive and -resistant strains unlike the {3-
lactams and macrolides. No penicillin-resistant strains were susceptible to {3-
lactams. and only 38% of these strains were susceptible to macrolides.
Condusions: Based on these findings. moxifloxacin should be further
investigated as a therapeutic option for infections caused by multiply
resistant S. pneumoniae.
[WeP11611n-vitro comparison of the phototoxic potential of
dprofloxacin, lomefloxacin and moxifloxadn on human corneal
fibroblast cells
J. Sunderland I , C. Tobin', L. White', A. MacGowan l , C. Rogersl , M.
Berry2
BCARE, I Southmead Hospital; ZBristol Eye Hospital. Bristol, United Kingdom
Objectives: The fluoroquinolones (FQ) have a good safety profile, but it is
known that some can evoke phototoxic reactions. We compared the
phototoxic potential of ciprofloxacin (CPX). Iomeftoxacin (LMX) and
moxifloxacin (MOX) on human corneal fibroblast cells.
Methods: Human corneal fibroblast cells were exposed to 0, 26. 65. 130,
195.260 /-1M FQ solutions and a O. 6. 8J/cm2 UVA dose. Cell numbers after
treatment were determined by a spectrophotometric hexosamidinase assay
and compared to the control containing no drug. HPLC was employed to
determine photodegradation ofFQ.
Results: The rank order ofFQ photolability was LMX > CPX > MOX.
After 6 J/cm2 UVA. CPX ~ 195 /-1M and LMX ~ 65 #-1M resulted in a
significant reduction ofmean cells/well (CPX p < 0.02; LMX P < 0.002).
No MOX concentration tested resulted in a significant reduction in mean
cells/well. After 8J/cm2 UVA CPX ~ 130/-IM and LMX ~ 26 #-1M resulted
in a significant reduction in mean cells/well (CPX p < 0.002; LMX P <
0.(02).
Conclusions: CPX and LMX demonstrated concentration dependant
phototoxicity to corneal fibroblast cells and parent drug photodegradation.
MOX demonstrated no phototoxic response and showed little photode-
gradation after irradiation. MOX may be a good alternative to CPX as an
ocular infection FQ with its superior photostability.
IWeP11711n vitro activity and pharmacodynamics of
moxlfloxacin and five quinolones against S. pneumonlae
L. Saravolatz. O. Manzor. C. Check, A. Felczak
St.Jolm Hospital & Waytie State University, Detroit, USA
Objectives: We conducted an in vitro study of 203 recent isolates of S.
pneumoniae including resistant. intermediate, and susceptible strains to
determine the relative activity and pharmacodynamic parameters for six
quinolones.
Methods: the antimicrobial agents tested were moxifloxacin, grepaftoxacin,
trovafloxcin, levoftoxacin, clinaftoxacin. and sparftoxacin. The S. pneuma-
niae isolates tested (N = 203) included 55 penicillin sensitive (PSSP), 80
penicillin intermediate (PISP), and 68 penicillin resistant (PRSP) strains.
Susceptibilities were performed by broth rnicrodilution according to the
Nflrional Committee for Clinica.l Laboratory Stnndardl. Phannaeodynamic;
parameters calculated included the therapeutic index, T.!. = peak serum
concentration divided by the MIC90 and the AUIC = the area under the
curve divided by the MIC90. Susceptibilities for PSSP. PISP, and PRSP
were simiIiar.
Results
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Antimicrobial M1C90 T.I. AUIC
Moxifloxacin 0.13 34.6 369
Clinafloxacin 0.13 12.3 68
Trovafloxacin 0.25 12.4 138
Grepafloxacin 0.25 5.6 44
Sparfloxacin 0.5 4.0 42
Levofloxacin 1 5.7 48
Condusions: Moxifloxacin and Trovafloxacin were the most active quino-
lones against recent isolates of penicillin sensitive and penicillin resistant S.
pneumoniae. The pharmacodynamic parameters of the quinolones evalu-
ated against S. pneumoniae suggest the following order of activity: moxi-
f10xacin > trovafloxacin > c1inafloxacin > grepafloxacin, sparAoxacin,
levofloxacin.
[WeP11il In vitro activity and pharmacodynamics of
gatifloxacin and six quinolones against S. pneumonlae
L. Saravolatz. O. Manzor, C. Check.]. Pawlak
St.Joh" Hospital & Wayne State U"iversity. Detroit, United States
Objectives: We conducted an in vitro study of 199 recent isolates of S.
pneumoniae including resistant, intermediate, and susceptible strains to
determine the relative activity and pharmacodynamic parameters for
seven quinolones.
Methods: the antimicrobial agents tested were gatifloxacin, grepafloxacin,
trovafloxcin, ciprofloxacin, levofloxacin. clinafloxacin, and sparRoxacin.
The S. pneumoniae isolates tested (N = 199) included 54 penicillin sensitive
(PSSP), 78 penicillin intermediate (PISP), and 67 penicillin resistant (PRSP)
strains. Susceptibilities were performed by broth microdilution according to
the National Committee for Clinical Laboratory Standards. Pharmacody-
namic parameters calculated included the therapeutic index. T.I. = peak
serum concentration divided by the MIC90 and the AVIC = the area under
the curve divided by the MIC90.
Results
Antimicrobial MIC90 T.I. AUIC
Gatifloxacin 0.5 9.2 71
Clinafloxacin 0.13 12.3 68
Trovafloxacin 0.25 12.4 138
GrepaAoxacin 0.25 5.6 44
Sp,arllox2cin 0.5 4.0 42
Levofloxacin 1 5.7 48
Cipro8oxacin 2 2.0 6
Conclusions: Gatifloxacin, Clinafloxacin and TrovaRoxacin were the most
active quinolones against penicillin sensitive and penicillin resistant S.
pneumoniae. The pharmacodynamic parameters of the quinolones evalu-
ated against S. pneumoniae suggest the following order of activity: trova-
f10xacin > gatifloxacin, clinafloxacin > grepafloxacin, sparfloxacin,
levofloxacin > ciprofloxacin.
IWeP11911n vitro emergence of resistance among methicillin-
resistant Staphylococcus aureus to ciprofloxacin, levofloxacin,
moxifloxacin, trovafloxacin or vancomycin
M. S. Rouse, K. E. Piper, R. Patel, Z. Temesgen, W. R. Wilson,]. M.
Steckelberg
Mayo CU"ic, Rochester, MN, U"ited States
Objectives: To compare the emergence ofrcsistance in vitro among cipro-
f1oxacin-susceptible clinical MRSA isolates exposed to ciproftoxacin (CP),
levoftoxacin (LV), moxiftoxacin (MX), trovaftoxacin (TV), or vancomycin
(VN).
Methods: Each of30 isolates was incubated in broth containing 1 mg/mL
CP, 2 mg/mL LV, 0.5 mg/mL MX, 2 mg/mL TV or 4 mg/mL VN (half the
recommended or NCCLS-approved resistance breakpoints) for 24 h.
Following incubation, each culture was divided into two aliquots. One
aliquot was recultured in fresh antibiotics. The second aliquot was inoculated
onto screening plates containing 2 mg/mL CP, 4 mg/mL LV, 1 mg/mL MX,
4 ml/;/mL TV, or 8 mg/mL VN. MIC tests were performed on MRSA
recovered from the screening plates.
Results: Initial MIC90 of30 isolates ofMRSA was I mg/mL CP, 0.25 mgt
mL LV, £0.125 mg/mL MX or TV, and 2.0 mg/mL VN. After 10 days
exposure. the MIC90 of the 30 isolates of MRSA was 8 mg/mL CP, 4 mg/
mL LV, I mg/mL MX, 0.5 mg/mL TV and 2 mg/mL VN. CP resistant
MRSA were detected after 1 day of exposure to CP, LV resistant MRSA
were detected after 7 days exposure to LV, MRSA with MX MIC ef2 ug/
mL were detected after 9 days exposure to MX. Resistance was not detected
after daily incubation with TV or VN.
Conclusion: Among 30 ciproBoxacin-susccptible clinical isolates ofMRSA,
resistant bacteria were detected in vitro significantly (P < 0.05) more
frequently after exposure to CP than to LV, MX. TV, or VN.
IWeP120I Intracellular targets that avoid fluoroquinolone
resistance in Streptococcus pneumoniae
J.J. Millichap, E. Pestova, R. Beyer, L. R. Peterson
Northwestern U"iversity. Chicago, United States
ObjectIves: To evaluate the structurally distinct ciproftoxacin,levoftoxacin,
moxiftoxacin, sparAoxacin and trovaftoxacin for i" vitro activity against S.
p'leumoniae, and to assess intracellular targets and susceptibility to efflux.
Methods: Susceptibility was determined according to NCCLS methods.
Mutants were obtained by exposing S. pneumoniae to doubling drug
concentrations starting at the MIC, using 108-109 cells plated onto the
top ofa two-layer plate. Nucleotide sequences ofparC, parE. gyrA and gyrB
fragments were determined. Reserpine effect to measure active efflux was
done by growth inhibition using S. pneumoniae at 1-2 x 106 cells/mI in broth
medium containing ftuoroquinolones at If. their MIC, either alone or with
10 p,g/ml ofreserpine. Measurements of00550 were determined over 6-7
hours at 35°C.
Results: Moxifloxacin was active at MIC ~ 0.25 mg/L against mutants of
ciproftoxacin or levoftoxacin having a Ser79~Phe/Tyr substitution in ParC.
The C-8 substituted quinolones sparAoxacin and moxiftoxacin targeted
GyrA as an initial lethal event. Reserpine enhanced levofioxacin and
ciproftoxacin activity by 9.0-79.0%, but only 0-11.0% for sparAoxacin,
trovaftoxacin and moxifloxacin, showing that the latter three are poor
substrates for efflux.
Conclusions: Optimal activity offluoroquinolones appears due to enhanced
action against both DNA gyrase and topoisomerase IV, and to reduced
efflux. A methoxy substituent at position 8 enhances overall type n
topoisomerase action. At position 7, the best substituents have considerable
bulkiness that impedes the efficiency of efflux proteins. Optimal structural
configuration at these rwo sites lowers the ability for the development of
drug resisu.nce.
IWeP121I Antianaerobic activity of moxifloxacin compared
with those of ciprofloxacin, imipenem and metronidazole
L. Dubreuil. E. Singer, E. Behra-Miellet
Faculty ofPharmacy. Lille, Frarlce
Objectives: MICs were determined on moxiftoxacin (MXF), ofloxacin
(OFL), ciproftoxacin (CIP) , clindamycin (CLN), imipenem (IMI) and
metronidazole (MOL) against 159 anaerobes isolated from human clinical
samples.
Methods: Reference agar dilution (standard Mil A4, NCCLS).
Results: MXF, OFL and CIP inhibited at 4 mg/L respectively 96, 64 and
21 % ofthe B.fragilis group swains whereas resistance rates were respectively:
MOL 0%, CLN 27%, IMI 2.6%.
Considering the three ftuoroquinolones, the MICSO/90s (mg/L) were:
Microorganisms (N°) MXF OFL CIP
B·ftagilis group (76) 0.5/2 4/16 8/64
Other gram-negative (24) 0.125/0.25 1/4 0.5/1
C. p"ftingrns (11) 0.25/0.25 0.5/0.5 0.25/0.25
C. diffidk(10) t/l 4/8 8/8
Non-sporulated rods (17) 0.25/1 1/2 0.5/4
Peptostreptococcus (18) 0.25/1 4/16 1/4
All gram-positive (59) 0.25/1 2/16 I/R
All anaerobes (159) 0.25/1 2/16 4/32
MXF, unlike other ftuoroquinolones, demonstrated high activity against
the B..fragilis group and clostridia. MXF was also more potent than OFL and
CIP against Gram-positive rods and anaerobic cocci. Over all 159 anaerobes,
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MXF inhibited 93, 95 and 98% of the strains investigated at concentrations
of I, 2 and 4 mg/L, respectively.
Conclusions: The broad anaerobic spectrum of MXF demonstrated in vitro
is promising to treat intra-abdominal infection. Further clinical evaluation is
needed.
IWeP122I The comparative in vitro activity of ciprofloxadn
and levofloxacin against clinical strains of Pseudomonas
aeruginosa
F. H. M'Zali', P. M. Hawkey!, c.J. Thomson2
'University ofLeeds & Leeds General Infirmary, Leeds; lUK Bayer pic,
Newbury, United Kingdom
Objectives: There is conflicting evidence published regarding the ability of
ciprofloxacin and levofloxacin to select resistant mutants in Pseudomonas
aeruginosa. The aims of the study were to determine whether ciprofloxacin
and levofloxacin differ in their propensity to select resistant mutants and the
effect of temperature on this selection.
Methods: Spontaneous ciprotloxacin- and levotloxacin-resistant mutants of
25 clinical strains of Pseudomonas aeruginosa from different geographical
locations, including the NCTC reference strain 10662, were isolated on
fsoSensitest agar plates containing either ciprofloxacin or levofloxacin at 4x
and 8 x the MIC ofthe parent at two different temperatures, 37"C and 30°C.
Results: The isolates had different susceptibility to ciprofloxacin and levo-
f10xacin (MIC ranges 0.05-8 mg/I and 0.1-16 mg/I, respectively). The mean
single-step resistance rates to 4x and 8 x MIC were lower with ciprotloxacin
than with levofloxacin. These differences were observed at both tempera-
tures employed to select mutants. Differences were statistically significant (p
< 0.001). When the isolates were exposed after 10 passages to subinhibitory
concentrations of both antibiotics to select incremental mutations, the MIC
ofthe isolates was increased with both quinolones, but resistance developed
more rapidly with levofloxacin than with ciprofloxacin. The mutants
showed complete cross resistance between the two antibiotics.
Conclusions: The comparison of the in vitro activity of ciprofloxacin and
levofloxacin against P. aerugi"osa strains suggest that ciprofloxacin has a
better intrinsic antibiotic susceptibility than levotloxacin. It also shows that
pre-existing ciprofloxacin resistance does not influence the development of
resistance in P. aeruginosa.
[WePU3] Ability of Moxifloxacin (MXF) and other
fluoroquinolones to select resistant Staphylococcus aureus
L.]. V. Piddock, H. Marona, Y. FangJin
University ofBirmingham, Birmingham, United Kingdom
Objectives: To determine whether different f1uoroquinolones seleet resis-
tant S. aureus with the same frequency of resistance, and/or the same
phenotype, and/or the same or different mutations in the same or different
genes.
Methods: Wildtype S. aureus (F77) plus two mutants derived from this
strain (F193 and FI94), both containing single mutations in grlA (Ser80 to
Phe and SerSO to Tyr, respectively), were exposed to moxifloxacin (MXF),
SPAR, OFX, GREP, LEV and TROV at concentrations of2, 3, 5 and 10
/-lg/mJ ofeach agent in agar. The susceptibility ofall mutants was determined
to 14 antibiotics by the agar dilution method.
Results: All agents, except SPAR and TROV, selected mutants from F77 at
frequencies of 1 x 10-9 to 8 x 10- 11. OFX did not select any mutant F193.
Onlyat3 x MICofMXF,GREP,LEV, TROV were mutant F193 selected.
Only 3 x MIC of LEV and 10 x MIC OFX selected mutant F194. All
mutants were f1uoroquinolone resistant; few were multiply antibiotic
resistant. This was confirmed by molecular analyses; most mutants contained
one or more mutations ingyrA and/or grlA.
Conclusions: (i) The same phenotype was selected irrespective of the
selecting agent; (ii) the phenotype of the mutant was influenced by the
parent strain and not the agent.
IWeP1241 Gradient plates for the study of quinolone
resistance
F. M'Zali', P. Hawkey', C. Thomson2
'University ofLeeds & Leeds General Infirmary, Leeds; lBayer pic, Neu.bury,
United Kingdom
We describe a rapid and economic method for screening for bacterial
mutants resistant to quinolone antimicrobials and for the study of cross
resistance.
Square plates (10 cm2) are poured with two layers of agar. The bottom
layer consists of 20 ml of IsoSensitest agar which is allowed to set with the
plate slantedjust sufficiently so that the entire bottom is covered. Another 20
mJ of agar containing the quinolone antibiotic are added after placing the
petri dish in a horizontal position. In this way, plates with a proportional
inerease of the antibiotic concentration along one horizontal axis are
obtained. One mI of an overnight bacterial culture (107_109 CFU/ml) is
spread uniformly over the surface of the plate. Only resistant mutants will
form colonies beyond the boundary of the minimum inhibitory concentra-
tion (MIC). By streaking out isolated colonies, resistance can be confirmed
and incrementally increased by serial passage. The degree ofresistance (DR)
is estimated by dividing the antimicrobial concentration required to inhibit
90% ofthe colonies growing beyond the area ofthe MIC by the MIC itself.
This technique provides an efficient method for detecting spontaneously
resistant mutants and estimating their spread along the gradient. It has also
proved successful in comparing the in vitro activity of ciprofloxacin,
levofloxacin, grepatloxacin, trovafloxacin and moxitloxacin against a wide
variety ofclinical isolates ofStaphylococcus aureus, Staphylococcus saprophyticus
and Pseudomonas aeruginosa. Mutants resistant to these quinolones have also
been selected using this technique, and their molecular characterization is
currently under investigation.
IWeP12SI/n vitro selection of resistant mutants of methicillin
sensitive (MSSA) and resistant (MRSA) Staphylococcus aureus by
new quinolones by multistep assay on 10 days
Y. Rio, F.Jurin,]. Didion
Laboraloire de BlUltriologie eHR Metz, France
Four clinical strains of MSSA and two MRSA were grown with a set of
concentrations (0.06-256 mg/L) in Brain Heart Infusion of 4 ftuoroquino-
lones (FQs): oftoxacin (OFL) , levoftoxacin (LEV), trovafloxacin (TRO),
moxitloxacin (MXF). After overnight incubation, the last concentrations
with visible growth were diluted IO-fold and used to inoculate a set of the
same concentrations of FQ, and repeated during the 10 days following.
MICs were determined each day, by using Mueller Hinton plates eontaining
serial geometric dilution of the FQ. Each experiment was performed three
times.
The parental MICs for OFL and LEV of MSSA are included between
0.125-0.5 and 0.03-0.06 mg/L for TRO and MXF. Respectively, the values
for MRSA range from 1-4 and 0.125-0.5 mg/L. The final MICs were
similar for MRSA and MSSA and reached 64-128 mg/L with OFL, LEV
after 7 days and 32-64 mg/L with TRO, MXF after 9 and 10 days. The
MIC's curve by time are exponential for the four FQs with a slope in
logarithm in base 2 higher + 1.20 for OFL, LEV, TRO and lower 0.90 with
MXF. MICs ofMRSA rise quickly with OFL, LEV in 6 days. With MXF.
MICs don't increase above 1 mg/L for 6 days before reaching the final MICs
in 10 days. An MIC of 16 mg/L (resistance criteria) is obtained after 4 days
with OFL, LEV, 6 days with TRO and 8 days with MXF.
Selection at high level is obtained with the four FQs without difference of
MIC between MSSA and MRSA after 10 days. The emergence's kinetics of
resistant mutants to these 4 FQ is dissociated. With MXF, resistance stays at a
low level « 1 mg/L) during 6 days.
IWeP1261 Type" topoisomerase mutations associated with
f1uoroquinolone resistance in clinical isolates of Streptococcus
pneumoniae
C. Duncan ' ·2, D. Bast l.2, L. Kilbum l.2, H. MacKenzie3, R. Davidson3, L.
Mandell4, D. Low1•2.]. de Azavedo'·2
'Mount Sinai atld Princess Margaret Hospitals, Toronto, Ontario; lUniversity
of Toronto, Ontario; JQueen Elizabeth II Health Science and Dalhousie
Un;I'ersity, Halifax, Nova Scotia; 4McMaster University, Hamillon, Ontario,
Canada
objectives: Huoroquinolonc (FQ) re,inanec in S. pneumotliae (SPN) has
been attributed to amino acid substitutions in the quinolone-resistance-
determining regions (QRDR) of DNA gyrase (gyrA and gyrB) and
topoisomerase IV (pare and parE). We looked at these mutations in a
range of clinical SPN isolates of different serotypes as part ofa study on FQ
usage in Canada.
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Methods: Susceptibilities to ciprofloxacin (CIP) in 99 clinical isolates of
SPN were examined by broth microdilution according to NCCLS guide:-
lines. The QRDR regions of parC, gyrA and parE of all strains were
amplified by PCR and sequenced. The QRDR region of gyrB was only
analysed for strains with a CIP MIC of ~16 mg/L. Active efflux was
examined by agar dilution in the presence ofCIP and reserpine.
Results: CIP MICs ranged from 0.25 to 64 mglL. Among strains with a CIP
MIC of ~2 mg/i, the predominant substitution was Ser-79-Phe/Tyr in
ParCo Increasing CIP MICs were associated with a Ser-8I-Phe/Tyr or Glu-
85-Gly/lys substitution in GyrA. A single strain with a CIP MIC ofl6 mg/
l. which did not have a substitution in GyrA, showed a 16-fold decrease in
MIC in the presence ofreserpine, suggesting the presence ofactive efflux. No
AA substitutions were found in GyrB.
Conclusions: Increasing CIP MICs were associated with amino acid sub-
stitutions in ParC followed by substitutions in GyrA. While this phenom-
enon has been shown in vitro, to our knowledge this is the largest study
showing detailed genetic analysis of clinical isolates exposed to FQ usage.
IWePU7] Bactericidal activity of moxifloxacin compared to
that of penicillin Gagainst penicillin-sensltive (5) and -resistant
(R) Stleptococcus pneumoniae
Cornelia Wilhelm. Pramod M. Shah
University Hospital, D-60590 Frankfurt am Main, Germany
Objectives: Compare bactericidal activity of moxifloxacin with that of
penicillin G against penicillin sensitive (S) and resistant (R) strains.
Method: Number of surviving colony forming bacterial after exposure to
concentrations equal to 0.1, 1.0 and 10 times their respective minimum
inhibitory concentration (MIC in mg/I) was determined by subculturing
aliquots on blood agar plates. Table below gives time needed to reduce the
inoculum by 99.9%.
Time (in minutes) required to reduce the inoculum by 99.9%
Strain Penicillin Moxifloxacin
0.1 1.0 10.0 0.1 1.0 10.0
405 o.a. 300 360 n.a. n.a. 300
505 0.3. 240 300 n.a. n.a. 240
615 0.3. 300 300 n.a. n.a. 90
625 n.a. n.a. 180 n.a. n.a. 90
13R 0.3. 360 180 n.a. n.a. 240
21 R n.a. o.a. 3<.0 n.3. 360
53R 0.3. 300. 300 n.a. n.a. 60
56R n.a. n.a. n.a. n.a. n.a. 120
56R n.a. n.a. n.a. n.a. o.a. 120
11.3. = not achieved
Conduslons: Only penicillin reduced inoculum by 99.9% at I MIC. At 10
MIC there was no difference between the two agents.
IWeP12S! Activity of gemlfloxacin against gram negative
bacteria containing plasmid pMG252 conferring resistance to
quinolones
A. Pascual. L. Martinez-Martinez, P.Joyanes. t. Garcia, E.]. Perea
Dpt ojMicrobiology, School ojMedicine, Sevilla, Spain
Objetives: To determine the in vitro activity of gemifloxacin (GFX) against
wild and laboratory derived mutants of gram negative bacteria containing
pMG252.
Methods: Five wild-type strains (E. coli J53, P. aerugillosa PU21, K.
pneumoniae C3, C. freundii 006 and Salmonella spp HUSI) and E. coli
laboratory strains and derived mutants with mutations in gyrA, gyrB.
parC, ompF, ompC, auA, em,B and marR containing or not pMG252 were
studied. MICs and MBCs were determined by microdilution according to
NCCLS guidelines. The results were compared with those ofciprofloxacin
(CPX).
Results: MICs and MBCs ofGFX were similar to those ofCPX indepen-
dently ofthe presence ofpMG252. MICs and MBCs ofGFX against plasmid
containing strains were 4-128 and 2-256 times higher respectively than
those against wild type strains. Similarly, the presence ofpMG252 caused 2-
128 times increase in the MICs and MBCs ofGMX against strains containing
specific mutations conferring quinolone resistant. Nevertheless, all strains
(wild type and mutants) except the marR and the gyrA/parC mutants,
carrying pMG252 were inhibited by I mg/l ofgemifloxacin. Similar results
were observed for CPX.
Conclusions: MICs and MBCs of GFX against Gram negative bacteria
increases several times when the strain contains pMG252. This increase is
added to the basal level ofresistance due to mutations already known to cause
quinolone resistance.
[WeP129] A nordic study of activity of moxifloxacin,
levofloxacin and other antimicrobial agents against respiratory
pathogens
L. E. Nilsson, H. Hanberger
The SCOPE Study Group; University Hospital, Linkiiping, Sweden
Objectives: To study the antibiotic susceptibility of respiratory pathogens.
Methods: Initial respiratory isolates (N = 901) from patients at primary
care units (N = 690), intensive care units (ICUs) (N = 126) and non-ICU
hospital wards (N = 6c)() at 12 hospitals and counties in Denmark, Finland
and Sweden were collected during 1999. Minimal Inhibitory Concentra-
tions (MICs) were determined using Etest (AB Biodisk). MIC breakpoints of
the National Committee for Clinical laboratory Standards (NCClS) were
used. ,lj-lactamase production was tested with the nitrocefin test (AB
Biodisk).
Results: The following activity levels were found among 359 Haemophilus
inj/uenzae isolates (MIC50. MIC90, % resistance), Ceftriaxone (C) (0.006,
0.016, 0), Doxycycline (D) (2, 4. 4), levofloxacin (L) (0.75, I, 0), Moxi-
floxacin (M) (0.125,0.19, -), TMP/SMX (TS) (0.5, I, 8). 164 isolates of
Moraxellacatarrhalis, C (0.064. 0.75, -). D (0.75,2, -), 1 (0.064, 0.094,0), M
(0.094,0.125, -), TS (0.5, I. -),256 isolates of Streptococcus pneumoniu, C
(0.008.0.032.0). D (0.125, 0.19, 4), Erythromycin (E) (0.094.0.125,4), 1
(0.75. 1,0), M (0.19, 0.25, -), Penicillin (P) (0.012,0.047,9% intermediate.
0% resistant) and 122 isolates of Streptococcus pyogenes C (0.023,0.047.0), D
(0.25.16,32), E (0.125, 0.5, 8), 1 (0.5, 1,0). M (0.19,0.25,0). ,lj-lactamase
production was detected in 6% and 77% of the H. inj/uenzae and M.
catarrhalis isolates, respectively. The MIC50 and MIC90 of the isolates from
primary care units, ICUs and non-ICU hospital wards were similar.
Conclusions: The resistance rates of H. inj/uenzu for D and the resistance
rates ofS. pyogenes for D and E were higher than in earlier studies performed
by the Swedish Reference Group for Antibiotics. Similar activities oeL and
M were found against H. inJluenzu, M. catarrhalis, but M showed higher
activity than L against S. pneumoniae and S. pyogenes.
IWeP130 lin vitro activity of qulnolones against Borrelia
burgdorferi isolates
K. P. Hunfeld,J. Weigand. P. Kraiczy, T. A. Wichelhaus, P. Heisig, V.
Schafer, V. Brade
Institute ofMedical Microbiology, University Hospital ofFrankfurt/M.,
Germany
Objectives: To analyze the effectiveness of group I-VI quinolones against
Borrelia burgdorferi.
Methods: In the present study the minimal inhibitory concentrations
(MICs) of group I-VI quinolones against Borrelia burgdorjeri S.S. (N = 3),
Borreliagarinii (N = 3), Borrelia aJzelii (N = 3), Borrelia valaisiana (N = I),
and Borrelia bissettii (N = I) isolates. After 72 h of incubation MICs were
determined in vitro by use ofa new standardized colorimetric microdilution
method. The applied test system is based upon the software assisted kinetic
measurement ofcolor changes that occure in the presence ofphenol red and
result from the accumulation of non volatile acid produced by actively
metabolizing spirochetes.
Results: MIC values were lowest for gatifloxacin (MIC90: 1.0 Itg/rol),
sparfloxacin (MIC90: 0.7 JLg/ml), and gemifloxacin (MIC90: 0.125 ltg/
rol). MICs oflevofloxacin (MIC90: 4.0 Itg/rol), ciprofloxacin (MIC90: 2.0
Itg/ml) were clearly higher whereas nalidixic acid (MIC90: ~128 ltg/mIl
showed no effect on the growth of spirochetes. Mean minimal borreliacidal
concentrations (MBCs) were determined for gemifloxacin (MBC: 1.8 ltg/
ml/). ciprofloxacin (MBC: 13.8 Itg/ml), and nalidixic acid (MBC: > 128/Lg/
rol) by employing conventional subculture for three weeks in combination
with dark-field microscopy.
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COnclusions: Our srudy revealed in vitro activity of some modem quino-
lones against botrelia and underscores a possible suitability for the stage-
dependent therapy of Lyme disease.
IWeP131I A nordic study of activity of levofloxacin,
moxifl.oxadn and other antimicrobial agents against
staphylococd
L. E. Nilsson, H. Hanberger
The SCOPE Study Group; University Hospital, Linkopillg, Sweden
Objectives: To study the antibiotic susceptibility of staphylococci.
Methods: Initial isolates of staphylococci (N = 472) from patients at
primary care units (PCUs) (N = 161), intensive care units (lCUs) (N =
145) and non-ICU hospital wards (N = 165) at 12 hospitals and counties in
Denmark, Finland and Sweden were collected during 1999. Minimal
Inhibitory Concentrations (MICs) were determined using Etest (AB Bio-
disk). MIC breakpoints of the National Committee for Clinical Laboratory
Standards (NCCLS) were used.l1-lactamase production was tested with the
nitrocefin test (AB Biodisk).
Results: I1-lactamase production was detected in 82%, 64%, 81 % ofthe 236
isolates of Staphylococcus aureus, the 156 isolates of Coagulase Negative
Staphylococci (CNS) and the 79 isolates of Staphylococcus epidermidis,
respectively. The activity oflevo/loxacin (L), moxi/loxacin (M), vancomy-
cin (V) and teicoplanin (T) (MICSO mg/l, MIC90 mg/l) for the S. aureus
isolates, L (0.19,0.25), M (0.047,0.064), V (2,4). T (2, 4), the CNS isolates L
(0.19,32), M (0.094,2), V (2, 4), T (4, 16) and the S. epidermidis isolates L
(0.38,32), M (0.094,2), V (2,4) and T (4, 16). The following resistance rates
(%) were found among the isolates ofS. aureus (PCU, ICU, non-ICU ward)
Oxacillin (0) (0, 3, 1), Vancomycin (V) (0,0,0), Clindamycin (C) (2,0,0),
Gentamicin (G) (0,0,0), Levo/loxacin (L) (I, O. 1). Rifampicin (R) (0, O. 0),
TMP/SMX (TIS) (1,0,0), CNS 0 (18,69,54), V (0, 0, 0), C (14. 52, 31), G
(26,60,28), L (20, 54, 30), R (0,73.17) TIS (27, 66, 39) and S. epidermidis 0
(43,71,44), V (0, 0, 0), C (22, 45, 40), G (6,45,30), L (28,32,30), R (0,13,
10), TIS (50,65,47).
Conclusions: The resistance rates ofS. aureus were low, but the rates ofCNS
and S. epidermidis were high except for V. The highest rates was found at the
ICUs and the lowest at the PCUs. M showed higher activity than L against
the staphylococci. V showed higher activity than T against the CNS and S.
epidermidis isolates.
IWeP1321 A nordic study of activity of moxifloxadn and
other antimicrobial agents against the Bacteriodes tragilis group
L. E. Nilsson, H. Hanberger
The SCOPE Study Group; University Hospital, Linkoping, Sweden
Objectives: To study the antibiotic susceptibility the Bacteriodes fragilis
group.
Methods: Initial isolates of the Bacteriodes fragilis group (N = 117) from
patients at intensive care units (ICUs) (N = 36) and non-ICU hospital wards
(N = 81) at 12 hospitals in Denmark, Finland and Sweden were collected
during 1999. Minimal Inhibitory Concentrations (MICs) were determined
using Etest (AB Biodisk). MIC breakpoints of the National Committee for
Clinical Laboratory Standards (NCCLS) were used.
Results: The following activity levels were found among isolates of the
Baeteriodes fragilis group from patients at the ICUs (MIC50, MIC90, %
resistance), clindamycin (I, 8, 25). imipenem (0.06, 0.25. 0), metronidazole
(0.5, 1,8.3), moxi/loxacin (0.75,32, -), penicillin G (16, 128, -). piper-
acillin/tazobactam (0.625, 8, 0). The following activity levels were found
among isolates of the Bacteriodes fragilis group from patients at the non-ICU
wards (MIC50, MIC90, % resistance), clindamycin (1, 3, 16), imipenem
(0.094, 0.25, 0), metronidazole (0.875, 2, 1.2), moxi/loxacin (0.5, 4, -),
penicillin G (16,32, -), piperacillin/tazobaetam (PIT) (0.75,8,0).
Conclusions: No resistance was seen for imipenem and piperacillin/tazo-
bactam among the isolates of the Bacteriodesfragilis group. Higher resistance
rates were found at the ICUs compared to non ICU-wards for clindamycin
and metronidazole. All tested antimicrobial agents showed higher MIC50
and MIC90 at the ICUs compared to non ICU-wards.
IWeP133! Alterations in DNA gyrase subunit Band
topoisornerase IV subunit Eassociated with resistance to
fluoroquinolones in Pseudomonas aeruginosa
J. Stenholf, S. Jalal, B. Wretlind
Div. ofClin. Bacteriol., Huddinge Univ. Hosp., Karolinska Institute,
Stockholm, Swedm
Objective: To investigate the role of mutations in DNA gyrase subunit B
(gyrB) and topoisomerase IV subunit E (parE) in fiuoroquinolone (FQ)
resistance in P. aeruginosa.
Methods: Quinolone resistance determining regions (QRDR) of gyrA,
gyrB, parC, and parE genes were sequenced from 19 P. aeruginosa strains with
different MICs to nor/loxacin (0.5- > 256 mg/L). Amino acids are given as
E. coli equivalents.
Results: Alterations in GyrB were found in four strains. Three of these
strains (MICs 16, 16 and 256 mg/L, respectively) had GyrA (Thr83 to lie) and
GyrB (Thrl46 to Asn). One strain (most resistant strain in the col1ection,
MIC > 256 mg/L) with GyrA (Asp87 to Asn) had three alterations in GyrB
(positions 234, 238 and 266). Three strains had alterations in ParE, and two of
these strains (MIC 8, Ser458 to Arg; MIC 32, Ala499 to Val) had no
alterations in QRDR of Pare. The third strain (most resistant strain in
the col1ection, MIC > 256) had ParC (Phe74 to lie) and ParE (Glu460 to
Val) alterations.
Conclusions: Alterations in GyrB and ParE seem to contribute to /Iuor-
oquinolone resistance in P. aeruginosa.
IWeP1341 Multicentric study for in vitro evaluation of
moxifloxacin and other antimicrobial agents against dinical
bacterial isolates from Argentina
H. Lopez·, A. Sucari!, S. Scarano!, V. Vilches!, D. Stepanik!, B.
Sarachian2, G. MikaelianJ , O. Cardeiiosa4, L. Lemme4
ICentro de Infectologia; 2Hosp. Britanico; JCentro Estudios Microbiol; 4Bayer
Pharmaceuticals, Buenos Aires, Argentina
Moxi/loxacin (MOX) is a new ftuoroquinolone that possesses a broad
antimicrobial spectrum. The aim of this study was to compare MOX
activity with other antimicrobial agents: penicillin (PE), amoxicillin
(AM), AM + c1avulanate, cefuroxime, ceftriaxone, azithromycin, clari-
thromycin, cipro/loxacin (CI), o/loxacin (OF), levoftoxacin (LE) and trova-
/Ioxacin (TV). 635 organisms were srudied. including S. pneumoniae (Spn).
H. inj/uenzae (Hi), M. catarrhalis (Me), S. pyogenes, S. aureus methicillin
susceptible (MSSA) and resistant (MRSA) strains, isolated during 1998-9 in
4 Medical Centers from Argentina. Dilution agar method was performed
following NCCLS recommendations. From 154 Spn, 78.6% were PE
susceptible, 17.5% intermediate and 3.9% resistant. 17.0% Hi and 94.9%
Me were I1-lactamase positive. MIC90 values (mg/I) for the quinolones
tested were:
n C[ OF LE TV MOX
S. pntumoniar [[5 2 2 [ 0.25 0.25
S. pyogttlrs 85 1 2 0.5 0.125 0.25
MSSA 89 0.5 0.5 0.25 0.06 0.06
MRSA 21 > 32 16 8 4 2
H. injluttlzae 86 0.03 0.06 0.016 0.03 0.03
M. catarrhalis 62 0.03 0125 0.03 0.03 0.06
These results suggest that MOX has an enhanced activity against gram
positive bacteria, particularly S. pneumoniae strains.
IWeP13S1 Does dprofloxacin pre-treatment influence the
susceptibility of Pseudomonas aeruginosa to phagocytosis?
I. Mayerl , E. Nagy·, e. G. Gemmell2
IClinical Microbiology, University ofSzeged, Hungary; 2Department of
Bacteriology, Glasgow Royal Infirmary, Glasgow, United Kingdom
Objectives: Pseudomonas aeruginosa remains a clinically impon'lnt p"thogen
in different infectious diseases. Furthermore, there is growing interest in
bacteria -leukocyte interactions, which play important roles in the cellular
response of the body. The effects of ciproftoxacin on the respiratory burst
and bactericidal activity of polymorphonuclear leukocytes (PMNs) were
examined.
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Methods: Eight P. aeruginosa isolates were obtained from clinical samples.
PMNs were freshly isolated from healthy human blood. Respiratory burst
was assessed by measurement ofluminol-enhanced chemiluminescence, and
the bactericidal activity of the PMNs was monitored via the loss ofbaeterial
viability (counting of colony-forming units). The bacteria were pre-treated
with ciprofloxacin at 0.5, 1.0 and 5.0 times MIC.
Results: The pre-treatment had no effect on bactericidal activity: nor on the
number of killed bacteria (5 x 102-2 x 103), neither on the time of action
(within I h, P > 0.1). After pre-treatment the respiratory burst started earlier
than in the untreated control (20 versus more than 90 min.). The respiratory
burst maximums are in between 1.5-7.0 mV and the response times are 10-
30 min.
Conclusions: The effects ofciprofloxacin on the bactericidal aL'tivity and the
respiratory burst differed and exhibited no clear connection with the
resistance (MIC) of isolates.
P:5/10 - Quinupristin/Dalfopristin
[WeP136] In vitro activity of qulnupristln/dalfopristin
(synercid) against gram-positive cocci Isolated from severe
infections in Poland
]. Krzyszton-Russjan. K. Nowak, W. Hryniewicz
Sera & Vaccines Central Research Laboratory, Warsaw, Poland
Objectives: To evaluate susceptibility to quinupristin/dalfopristin (Q-D) of
clinical isolates of major Gram-positive pathogens.
Methods: Two hundred and eighty-two clinical isolates of various Gram-
positive bacteria were used in the study. The collection consisted ofstrains of
Streptococcus pneumoniae (n = 40), S. pyogene.s (n = 10). Enterococcusfaecium
(n = 60), Staphylococcus aureus (MRSA, n = 40; MSSA, n = 60) and
coagulase-negative staphylococci. CNS (MRCNS, n = 42; MSCNS, n =
30). Susceptibility testing ofstreptococci was performed with E-tests, and of
staphylococci and enterococci - by disc-dilfusion method according to
NCClS. Strains observed as resistant to Q-D were additionally charac-
terised by MIC evaluation using E-tests and the agar dilution method in
accordance with the NCClS guidelines.
Results: All isolates of S. pneumoniae, S. pyogenes, and Staphylococcus spp.
were found susceptible to Q-D. Out of E. faecium strains two isolates
demonstrated resistance to this antibiotic. These isolates were characterised
by MIC values of4-8 Itg/m!. MICs ofQ-D for S. pneumoniae strains were
evaluated as 0.5-1.0 1Jg/ml, and for S. pyogenes strains - as 0.25-0.38Itg/m!.
Condusions: The study revealed a very high in vitro activity ofquinupristin/
dalfopristin against major Gram-positive pathogens. The antibiutic may be
very useful in treatment ofserious infections caused by multiresistant strains
(e.g. MRSA and vancomycin-resistant E.faecium).
IWeP137!ln vitro activities of quinupristin-dalfopristin.
Iinezolid. and new quinolones against over 1200 clinical isolates
of gram-positive bacteria in Taiwan
P. R. Hsueh!, L.]. Teng l ,].]. lu2,].]. WuJ , H.]. Pan l • Y. C. Chen!, S.
W. HOI, K. T. luh!
INational Taiwa" University; lTri-Service General Hospital; JNational
Cheng-Kung University Hospital, Taipei, Taiwan
Objectives: To determine the in vitro activities ofquinupristin-dalfopristin,
linezolid, and new quinolones for recent clinical isolates of gram-positive
bacteria.
Methods: A total of 1210 nonduplicate. clinical isolates of gram-positive
bacteria were recovered patients mainly treated at National Taiwan Uni-
versity Hospital (NTUH) from January 1996 to December 1999. These
isolates included 100 blood isolates of methicillin-resistant Staphylococcus
aureus, 461 ofcoagulasenegative staphylococci, 267 ofS. pneumoniae, 120 of
viridans streptococci, 150 ofVRE (vancomycin MICs of ~321Jg/ml).35 of
Leuconostocspp_spp., 8 ofPediococcus spp., and 69 ofLactobacillus spp. MICs of
these isolates for 12 antimicrobial agents were determined by using the
standard methods recommended by the National Committee for Clinical
Laboratory standards (NCelS).
Results: linezolid demonstrated the most potent activity (MIC90s, 2 1Jg/
ml) against all isolates tested. including MRSA. VRE, and vancomycin-
resistant bacteria. Quinupristin-dalfopristin showed limited activity against
vancvomycin-resistant E.faetium (MIC90, 16 pg/mL), Pediococcus (MIC90.
128 JIg/ml.), LeuconoSlOC (MIC90. 128 JIg/mL). and Lactobacillus spp.
(MIC90, 16 1Jg/ml). Moxifloxacin and trovafloxacin had good activity
against these isolates except for ciprofloxacin-resistant VRE and methicilIin-
resistant staphylococci.
Conduslons: Linezolid appears to be a promising antimicrobial agent for
the treatment of infections caused by gram-positive bacteria. Quinupristin-
dalfopristin is not a suitable alternative for managing infections due to
vancomycin-resistant E.faecium in Taiwan.
[WeP~ Antimicrobial combinations against MRSA .
S. Cassey. P. R. Chadwick
Salford Royal Hospitals NHS Trust, Salford, United Kingdom
Objective: To study the antibacterial effect of combinations of teicoplanin
en and quinupristin/dalfopristin (Q/D) with broad-spectrum antimicrobial
agents against MRSA (methicillin-resistant Staphylococcus aureus).
Methods: 10 diverse clinical isolates of MRSA were studied. MICs were
determined by Etest. Time-kill studies were performed using a broth
macrodilution method. Combinations oft and Q/D were studied with
ceftazidime, cefepime, piperaciIlin-tazobactam and meropcnem.
Results: T and Q/D alone had cidal and static activity respectively against
the isolates tested. Antagonism was demonstrated between T and Q/D for9{
10 isolates. Synergic or antagonistic effects were not generally seen with
combinations ofeither T or Q/D and broad-spectrum antimicrobial agents.
Conclusions: This srudy did not suggest any potential benefit or contra-
indication to the concurrent use of selected broad-spectrum antimicrobials
duting treatment ofMRSA infection with either T or Q/D. A potential for
antagonism between T and Q/D was demonstrated.
P:5/11 - Rifampicin
[WeP13SI Relationship between rpoB mutations in
Staphylococcus aureus and antimicrobial activities of rifampicin
and KRM-1648
T. A. Wichelhaus. V. Schafer, V. Brade. B. Boddinghaus
Institute ofMedical Microbiology, Frankfurt am Main, Germany
Objectives: This study was aimed at determining the in vitro antibacterial
activities of the rifamycin derivatives rifampicin and KRM-I648 against
Staphylococcus aureus and at correlating the level of resistance to both
rifamycins with the genetic alterations in the rpoB gene.
Methods: The in vitro antibacterial activities were determined against 150
Seaphylocouus aurt:'us isolates, induding 50 rifampicin_sensitive (R..ir) methi_
cillin-sensitive Staphylococcus aureus (MSSA), 50 Rif methicillin-resistant
Staphylococcus aureus (MRSA), and 50 rifampicin-resistant (Rif') MRSA.
Concerning RiF MRSA, the genetie alterations in the rpoB gene were
determined by PCR amplification and sequencing.
Results: The MICs of rifampicin and KRM-I648 for 90% ofRif Staphy-
lococ",s aureus isolates tested were 0.016 and 0.001 1Jg/ml, respectively.
Missense mutations within a 204 bp fragment covering clusters I and II of
the rifampicin resistance region could be demonstrated in all Rif" MRSA
isolates. The in vitro susceptibility testing of rifampicin and KRM-I648
against RiF MRSA isolates revealed different activities of the rifamycins
with respeL't to specific mutations within rpoB. Specific mutation sites could
be identified which exhibited high-level cross-resistance to both rifamycins.
while a subset of mutations were associated with an up to 100 fold better
activity ofKRM-l648.
Conclusions: The results provide evidence that the new rifamycin KRM-
1648 is a potent antimicrobial that displays a high activity even against a
subset of rifampicin-resistant Staphylococcus aureus isolates.
IWeP139[ Rapid detection of rifampidn resistance in
Mycobacterium tuberculosis clinical isolates using
mycobacteriophages
N. Galii,]. A. Dominguez, S. Blanco,]. lonca,]. M. Manterola, V.
Ausina
Servei de Microbiologia, Hospital Universitari Germans Trias i Pujol,
BaJalona, Spain
Objectives: To standardise a rapid, non-laborious and low-cost assay to
srudy the susceptibility of M. tulm-CIIlosis (MTB) clinieal ioolates to rif.lmpi-
cin by using myeobaeteriophage 029.
